Johnson & Johnson, a Dow component, will focus on a huge acquisition, some experimental drugs awaiting approvals and its ongoing recall and manufacturing quality issues when it reports second-quarter results before the stock market opens Tuesday.
...
J&J also must find a new manufacturer for its cancer drug Doxil, production of which has been shut down because the third-party manufacturer J&J used had contamination and other serious lapses at its factory. The resulting shortage has left many cancer patients in the lurch.
WHAT'S EXPECTED: Analysts polled by FactSet, on average, expect earnings per share of $1.29 on revenue of $16.71 billion.
LAST YEAR'S QUARTER: J&J reported profit of $1 per share on revenue of $16.6 billion.
...